Top

Journal of Gastrointestinal Surgery

Published in:

01-02-2010 | DeMeester Festschrift

Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors

Authors: Daniel Vallböhmer, Jan Brabender, Ralf Metzger, Arnulf H. Hölscher

Published in: Journal of Gastrointestinal Surgery | Special Issue 1/2010

Abstract

Introduction

Esophageal adenocarcinoma is the most rapidly increasing cancer in Western countries. Like esophageal squamous-cell carcinoma, these tumors are often detected at an advanced stage, requiring a multimodal concept. Despite improvements in detection, surgical resection, and (neo-) adjuvant therapy, the overall survival of esophageal cancer remains lower than other solid tumors. In fact, just 30–40% of the patients with advanced esophageal cancer benefit from a neoadjuvant therapy. Therefore, predictive/prognostic markers are needed to allow tailored multimodality therapy with increased efficacy.

Discussion

In recent years, there has been an exponential growth in our understanding of the cellular and molecular events associated with cell cycle regulation, programmed cell death, angiogenesis, and tumor growth. In this review, the classification of Hanahan and Weinberg is used concerning the six essential changes in carcinogenesis, i.e., the six hallmarks of cancer: (1) self-sufficiency in growth signals; (2) insensitivity to antigrowth signals; (3) avoidance of apoptosis; (4) limitless replicative potential; (5) sustained angiogenesis; and (6) tissue invasion and metastasis.

Conclusions

According to these six steps, this review provides an update of the most recent data about predictive/prognostic molecular markers in patients with esophageal cancer.

Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. doi:10.3322/canjclin.57.1.43.CrossRefPubMed

Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:112–127.PubMed

Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.PubMedCrossRef

Ando N, Ozawa S, Kitagawa Y et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–232. doi:10.1097/00000658-200008000-00013.CrossRefPubMed

Whooley BP, Law S, Murthy SC et al. Analysis of reduced death and complication rates after esophageal resection. Ann Surg. 2001;233:338–344. doi:10.1097/00000658-200103000-00006.CrossRefPubMed

Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729–746. doi:10.1016/S0039-6109(02)00029-4.CrossRefPubMed

Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–234. doi:10.1016/S1470-2045(07)70039-6.CrossRefPubMed

Greer SE, Goodney PP, Sutton JE et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172–177. doi:10.1016/j.surg.2004.06.033.CrossRefPubMed

Zacherl J, Sendler A, Stein HJ et al. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27:1067–1074.PubMed

10.

Brucher BL, Stein HJ, Zimmermann F et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963–971.PubMed

11.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi:10.1016/S0092-8674(00)81683-9.CrossRefPubMed

12.

Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett’s-associated neoplasia: correlation with prognosis. Mod Pathol. 1997;10:105–112.PubMed

13.

Inada S, Koto T, Futami K et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29:493–503. doi:10.1007/BF02482343.CrossRefPubMed

14.

Wilkinson NW, Black JD, Roukhadze E et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004;8:448–453. doi:10.1016/j.gassur.2004.01.006.CrossRefPubMed

15.

Gibault L, Metges JP, Conan-Charlet V et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107–115. doi:10.1038/sj.bjc.6602625.CrossRefPubMed

16.

Safran H, Suntharalingam M, Dipetrillo T et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391–395. doi:10.1016/j.ijrobp.2007.07.2325.PubMed

17.

Polkowski W, van Sandick JW, Offerhaus GJ et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1999;6:290–297. doi:10.1007/s10434-999-0290-2.CrossRefPubMed

18.

Brien TP, Odze RD, Sheehan CE et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35–39. doi:10.1016/S0046-8177(00)80195-1.CrossRefPubMed

19.

Aloia TA, Harpole DH Jr, Reed CE et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg. 2001;72:859–866. doi:10.1016/S0003-4975(01)02838-7.CrossRefPubMed

20.

Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004;91:666–672.PubMed

21.

Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:1323–1327. doi:10.1016/S0360-3016(03)00782-X.PubMed

22.

Kuwahara M, Hirai T, Yoshida K et al. p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus. 1999;12:116–119. doi:10.1046/j.1442-2050.1999.00034.x.CrossRefPubMed

23.

Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 1999;57:311–317. doi:10.1159/000012067.CrossRefPubMed

24.

Ikeda G, Isaji S, Chandra B et al. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999;86:1396–1405. doi:10.1002/(SICI)1097-0142(19991015)86:8<1396::AID-CNCR3>3.0.CO;2-H.CrossRefPubMed

25.

Sturm I, Petrowsky H, Volz R et al. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol. 2001;19:2272–2281.PubMed

26.

Brock MV, Gou M, Akiyama Y et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912–2919.PubMed

27.

Shimada Y, Watanabe G, Yamasaki S et al. Histological response of cisplatin predicts patients’ survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer. 2000;36:987–993. doi:10.1016/S0959-8049(00)00049-6.CrossRefPubMed

28.

Nakashima S, Natsugoe S, Matsumoto M et al. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res. 2000;20:1933–1937.PubMed

29.

Sohda M, Ishikawa H, Masuda N et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004;110:838–844. doi:10.1002/ijc.20215.CrossRefPubMed

30.

Takayama T, Nagao M, Sawada H et al. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J Surg Oncol. 2001;78:116–123. doi:10.1002/jso.1130.CrossRefPubMed

31.

Raouf AA, Evoy DA, Carton E et al. Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003;16:17–23. doi:10.1046/j.1442-2050.2003.00281.x.CrossRefPubMed

32.

Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med. 2001;7:413–417.PubMed

33.

Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–95. doi:10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9.CrossRefPubMed

34.

Vallböhmer D, Kuhn E, Warnecke-Eberz U et al. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2008;9:681–690. doi:10.2217/14622416.9.6.681.CrossRefPubMed

35.

Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer. 1998;83:652–659. doi:10.1002/(SICI)1097-0142(19980815)83:4<652::AID-CNCR4>3.0.CO;2-M.CrossRefPubMed

36.

Lord RVN, Salonga D, Danenberg KD et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000;4:135–142. doi:10.1016/S1091-255X(00)80049-9.CrossRefPubMed

37.

Vallböhmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV, DeMeester TR. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg. 2006;141:476–481. doi:10.1001/archsurg.141.5.476.CrossRefPubMed

38.

Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104. doi:10.1002/jso.20070.CrossRefPubMed

39.

Kuo KT, Chow KC, Wu YC. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg. 2003;76:909–914. doi:10.1016/S0003-4975(03)00717-3.CrossRefPubMed

40.

Takatori H, Natsugoe S, Okumura H et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008;34:397–402. doi:10.1016/j.ejso.2007.04.011.PubMed

41.

Han B, Liu J, Ma MJ, Zhao L. Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J Gastroenterol. 2005;11:2188–2192.PubMed

42.

Barclay C, Li AW, Geldenhuys L et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res. 2005;11:7683–7691. doi:10.1158/1078-0432.CCR-05-0771.CrossRefPubMed

43.

Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg. 2002;21:657–663. doi:10.1016/S1010-7940(02)00044-1.CrossRefPubMed

44.

Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002;86:552–557. doi:10.1038/sj.bjc.6600129.CrossRefPubMed

45.

Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004;127:1579–1586. doi:10.1016/j.jtcvs.2003.12.034.CrossRefPubMed

46.

Xi H, Baldus SE, Warnecke-Eberz U et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res. 2005;11:8341–8347. doi:10.1158/1078-0432.CCR-04-2373.CrossRefPubMed

47.

Krishnadath KK, Tilanus HW, van BM et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 1997;182:331–338. doi:10.1002/(SICI)1096-9896(199707)182:3<331::AID-PATH860>3.0.CO;2-D.CrossRefPubMed

48.

Murray GI, Duncan ME, O_Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998;185:256–261. doi:10.1002/(SICI)1096-9896(199807)185:3<256::AID-PATH115>3.0.CO;2-A.CrossRefPubMed

49.

Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004;67:300–309. doi:10.1159/000081331.CrossRefPubMed

50.

Tanioka Y, Yoshida T, Yagawa T et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116–2121. doi:10.1038/sj.bjc.6601372.CrossRefPubMed

Title: Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors
Authors: Daniel Vallböhmer
Jan Brabender
Ralf Metzger
Arnulf H. Hölscher
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue Special Issue 1/2010
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-009-1021-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors

Abstract

Introduction

Discussion

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Discussion

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Is Esophagectomy the Paradigm for Volume–Outcome Relationships?

Minimally Invasive Esophagectomy

Non-acid Gastroesophageal Reflux Measured Using Multichannel Intraluminal Impedance in Older Patients

Emerging Concepts of Bile Reflux in the Constellation of Gastroesophageal Reflux Disease

Introduction to Festschrift for Tom R DeMeester

Achalasia—If Surgical Treatment Fails: Analysis of Remedial Surgery